

Kevin R Bewley

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6739770/kevin-r-bewley-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

43
papers

6,938
citations

23
h-index

48
g-index

48
ext. papers

10,915
ext. citations

18.2
avg, IF

5.01
L-index

#	Paper	IF	Citations
43	Influence of Aerosol Delivered BCG Vaccination on Immunological and Disease Parameters Following SARS-CoV-2 Challenge in Rhesus Macaques.. <i>Frontiers in Immunology</i> , 2021 , 12, 801799	8.4	2
42	Finaxofloxacin, a Novel Fluoroquinolone, Reduces the Clinical Signs of Infection and Pathology in a Mouse Model of Q Fever.. <i>Frontiers in Microbiology</i> , 2021 , 12, 760698	5.7	0
41	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2021 , 396, 1979-1993	40	646
40	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021 , 397, 881-891	40	495
39	Quantification of SARS-CoV-2 neutralizing antibody by wild-type plaque reduction neutralization, microneutralization and pseudotyped virus neutralization assays. <i>Nature Protocols</i> , 2021 , 16, 3114-3140	18.8	56
38	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , 2021 , 184, 2348-2361.e6	56.2	549
37	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , 2021 , 184, 2201-2211.e7	56.2	269
36	A cautionary perspective regarding the isolation and serial propagation of SARS-CoV-2 in Vero cells. <i>Npj Vaccines</i> , 2021 , 6, 83	9.5	9
35	ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. <i>Communications Biology</i> , 2021 , 4, 915	6.7	9
34	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021 , 397, 99-111	40	2110
33	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021 , 27, 279-288	50.5	135
32	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021 , 27, 270-278	50.5	225
31	Prophylactic intranasal administration of a TLR2/6 agonist reduces upper respiratory tract viral shedding in a SARS-CoV-2 challenge ferret model. <i>EBioMedicine</i> , 2021 , 63, 103153	8.8	40
30	Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity. <i>Nature Communications</i> , 2021 , 12, 81	17.4	84
29	Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. <i>Nature Communications</i> , 2021 , 12, 1260	17.4	55
28	Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using and Models of Q Fever. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0067321	5.9	1
27	mRNA vaccination in people over 80 years of age induces strong humoral immune responses against SARS-CoV-2 with cross neutralization of P.1 Brazilian variant. <i>ELife</i> , 2021 , 10,	8.9	9

26	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. <i>Science Advances</i> , 2021 , 7, eabg7996	14.3	9
25	Dose-Dependent Response to Infection with Ebola Virus in the Ferret Model and Evidence of Viral Evolution in the Eye. <i>Journal of Virology</i> , 2021 , 95, e0083321	6.6	2
24	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021 , 27, 2032-2040	50.5	232
23	Intranasal Infection of Ferrets with SARS-CoV-2 as a Model for Asymptomatic Human Infection. <i>Viruses</i> , 2021 , 13,	6.2	32
22	Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike. <i>Cell Host and Microbe</i> , 2020 , 28, 445-454.e6	23.4	187
21	Development of a quantitative real-time RT-PCR assay that differentiates between Kyasanur Forest disease virus and Alkhurma hemorrhagic fever virus. <i>Ticks and Tick-borne Diseases</i> , 2020 , 11, 101381	3.6	1
20	Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens. <i>Scientific Reports</i> , 2020 , 10, 21894	4.9	12
19	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020 , 396, 467-478	40	1274
18	Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from Patients With COVID-19 and Identification of Deletions in the Viral Genome That Encode Proteins Involved in Interferon Antagonism. <i>Viruses</i> , 2020 , 12,	6.2	23
17	Antiviral Screening of Multiple Compounds against Ebola Virus. <i>Viruses</i> , 2016 , 8,	6.2	31
16	Sequence of pathogenic events in cynomolgus macaques infected with aerosolized monkeypox virus. <i>Journal of Virology</i> , 2015 , 89, 4335-44	6.6	6
15	Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model. <i>Journal of General Virology</i> , 2015 , 96, 3484-3492	4.9	94
14	Efficacy of liposome-encapsulated ciprofloxacin in a murine model of Q fever. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 5510-8	5.9	21
13	Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques. <i>Journal of Virology</i> , 2013 , 87, 7805-15	6.6	38
12	Animal models of Q fever (<i>Coxiella burnetii</i>). <i>Comparative Medicine</i> , 2013 , 63, 469-76	1.6	25
11	Real-time PCR system targeting a chromosomal marker specific for <i>Bacillus anthracis</i> . <i>Molecular and Cellular Probes</i> , 2008 , 22, 313-5	3.3	65
10	Nosocomial buffalopoxvirus infection, Karachi, Pakistan. <i>Emerging Infectious Diseases</i> , 2007 , 13, 902-4	10.2	33
9	Dengue virus serotype 3, Karachi, Pakistan. <i>Emerging Infectious Diseases</i> , 2007 , 13, 182-3	10.2	43

8	In vitro susceptibility of <i>Coxiella burnetii</i> to azithromycin, doxycycline, ciprofloxacin and a range of newer fluoroquinolones. <i>International Journal of Antimicrobial Agents</i> , 2004 , 24, 194-6	143	14
7	Poliovirus type 1 in working stocks of typed human rhinoviruses. <i>Lancet, The</i> , 2003 , 361, 1187-8	40	11
6	A black necrotic ulcer. <i>Lancet, The</i> , 2003 , 361, 1518	40	4
5	Convalescence from prototype SARS-CoV-2 protects Syrian hamsters from disease caused by the Omicron variant		2
4	Dose-dependent response to infection with SARS-CoV-2 in the ferret model: evidence of protection to re-challenge		21
3	Comparison of Rhesus and <i>Cynomolgus</i> macaques as an authentic model for COVID-19		3
2	Immunological and pathological outcomes of SARS-CoV-2 challenge after formalin-inactivated vaccine immunisation of ferrets and rhesus macaques		4
1	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. <i>SSRN Electronic Journal</i> ,	1	2